Press release
Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics - Pipeline Analysis 2019 Designations, Collaborations, and Other Developments
Download the sample report @ https://www.pharmaproff.com/request-sample/1206
MAPK inhibitors are being developed as small molecules, for the treatment of various types of cancer. They have also showed additional benefits with high effectiveness at lower concentrations in comparison to the ATP-competitive inhibitors, for the cancer therapy.
Get the detailed analysis @ https://www.pharmaproff.com/report/mapk-inhibitors-therapeutics
Mereo BioPharma Group plc is in the process of developing Acumapimod as an oral p38 MAPK inhibitor for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). eFFECTOR Therapeutics Inc., Genentech Inc., and Kura Oncology Inc. are some other companies having pipeline of MAPK inhibitors.
Request for customization @ https://www.pharmaproff.com/request-customization/1206
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics - Pipeline Analysis 2019 Designations, Collaborations, and Other Developments here
News-ID: 1681575 • Views: …
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates.
IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to…
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates.
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete…
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome.
Download the sample report at: https://www.pharmaproff.com/request-sample/1189
Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in…
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances…
More Releases for MAPK
Mitogen Activated Protein Kinase Inhibitors Market Trends Report | Advancements …
The global mitogen-activated protein kinase (MAPK) inhibitors market is witnessing substantial growth, driven by advancements in targeted cancer therapies, rising cancer prevalence, and increasing research and development (R&D) investments. MAPK inhibitors, essential in targeting specific signaling pathways involved in cancer progression, are crucial in managing various cancer types.
The market was valued at $5.43 billion USD in 2023 and is projected to grow from $5.98 billion USD in 2024 to $12.9…
Potassium Lauryl Phosphate (MAPK) Market Size, Share and Forecast By Key Players …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Potassium Lauryl Phosphate (MAPK) market is anticipated to grow at a compound annual growth rate (CAGR) of 13.27% between 2024 and 2031. The market is expected to grow to USD 8.1 Billion by 2024. The valuation is expected to reach USD 19.36 Billion by 2031.
The Potassium Lauryl Phosphate (MAPK) market is witnessing substantial growth, driven by its…
Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Market CAGR of 6 …
"Data Bridge Market research has recently issued comprehensive industry research on Global Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Market which includes growth analysis, regional marketing, challenges, opportunities, and drivers analysed in the report. The market insights gained through this Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics market research analysis report facilitates more defined understanding of the market landscape, issues that may interrupt in the future, and ways to position definite brand…
Global Potassium Lauryl Phosphate (MAPK) Market Research Report 2023-2029
Global Potassium Lauryl Phosphate (MAPK) Market: Driven factors and Restrictions factors
The research report encompasses a comprehensive analysis of the factors that affect the growth of the market. It includes an evaluation of trends, restraints, and drivers that influence the market positively or negatively. The report also outlines the potential impact of different segments and applications on the market in the future. The information presented is based on historical milestones and…
P38 MAPK Antibody Market would Register a Healthy Growth of USD 49.93 billion by …
The P38 MAPK Antibody report is an in-depth examination of the global P38 MAPK Antibody's general consumption structure, development trends, sales techniques, and top nations' sales. The research looks at well-known providers in the global P38 MAPK Antibody industry, as well as market segmentation, competition, and the macroeconomic climate. A complete P38 MAPK Antibody analysis takes into account a number of aspects, including a country's population and business cycles, as…
Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Market 2020 Indu …
Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Market 2020 report explains the growing popularity of the market competition by leading manufacturers or players, with sales volume, revenue (Million USD), price (USD/Unit), and market share for every individual manufacturer or player. Furthermore, the scope of this Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics Market report includes in-depth insights of global and regional markets with the sense given for variation in the growth of…
